Gennex Laboratories share news and announcements

BSE: 531739Pharmaceuticals & BiotechnologySmall Cap

₹8.70₹0.15 (1.69%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹8.85.

52-week range of traded prices to 23 Oct 2026

₹7.05Low, 30 Mar 2026₹17.25High, 28 Oct 2025

Market cap: ₹211 Cr2,248th largest listed
P/E: 11.5
P/B: 0.9
Dividend yield: Nonein the last 12 months
ROE: 9.0%
ROCE: 7.0%
Debt to equity: 0.15
Volume, BSE: 2,30,459

Gennex Laboratories share news and announcements

553 announcements, routine notices left out, newest first. Page 4 of 12.

Jun 2023
- 15 Jun · Second And Final Reminder-Cum-Forfeiture Notice For First And Final Call Money And Of Gennex Laboratories Limited - BSE Security ID: GENNEX, Script Code: 531739 & 890171
  This has reference to our letter dated June 13, 2023, wherein we had informed that the Right Issue Committee "Committee"), approved sending of a Second and Final reminder-cum-Forfeiture .... (opens in a new tab)
- 13 Jun · Second And Final Reminder-Cum-Forfeiture Notice For First And Final Call Money And Of Gennex Laboratories Limited
  This has reference to our intimation dated Nov 04, 2022 & Feb 07, 2022, we informed the exchange that the Company had received call money on 3,47,40,043 & 1,54,00,236 PPES out of 5,25,06,534 .... (opens in a new tab)
- 8 Jun · Approval From APIIC - Industrial Area Local Authority On Name Change
  We hereby inform you that the Name Change Approval from APIIC Industrial Area Local Authority, from M/s. Forel Labs Pvt. Ltd.to M/s. Deccan Remedies Limited, factory located at Plot No.58/A, .... (opens in a new tab)
- 6 Jun · Legal
  This has reference to emails dated 03.06.2023 of BSE. Please note that the Board Meeting to consider Financial Results held on 30.05.2023 had commenced at 16.30 p.m. on 30.05.2023 and .... (opens in a new tab)
- 1 Jun · Additional Details Regarding Time Of Commencement And Conclusion Of Board Meeting Of The Company Held On May 30, 2023;
  This has reference to your email dated 01.06.2023 regarding Additional Details Required for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015. In continuation .... (opens in a new tab)
- 1 Jun · License To Manufacture For Sale(Or For Distribution) Of Drugs Received Deccan Remedies Limited (Subsidiary Company) From Drug Control Administration Of Government Of Andhra Pradesh
  We hereby inform you that the Subsidiary of the Company, M/s. Deccan Remedies Limited, received license to manufacture for sale (or for distribution) of drugsfrom Drug Control Administration .... (opens in a new tab)
May 2023
- 31 May · Results
  We hereby inform to your good office that Consolidated Cash Flow Statement is missed to take in the submitted audited results due to the last minute rush on submission to the exchange. .... (opens in a new tab)
- 31 May · Approval From Pollution Control Board (PCB) On CFO Of Subsidiary (Deccan Remedies Limited)
  We hereby inform you that the Subsidiary of the Company, M/s. Deccan Remedies Limited, factory located at JNU Pharma city, Visakhapatnam got CFO approval from PCB on May 29, 2023 and the .... (opens in a new tab)
- 31 May · Results
  In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the quarter ended .... (opens in a new tab)
- 31 May · Results
  In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the quarter ended & .... (opens in a new tab)
- 30 May · Disclosure Under Regulation.23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 Of Gennex Laboratories Limited
  Pursuant to the provision of Regulation.23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the attached note on Related party Transaction .... (opens in a new tab)
- 23 May · Board meeting
  Meeting on 30 May 2023: audited results
- 20 May · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve With reference to the .... (opens in a new tab)
Apr 2023
- 29 Apr · Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (LODR) Regulations, 2015 Of Gennex Laboratories Limited For The Half Year Ended March 31, 2023;
  With reference to the above captioned subject matter, we are hereby enclosing the Compliance certificate Pursuant to Regulation 7(2) & 7(3) of the SEBI (LODR) Regulations 2015 for the half .... (opens in a new tab)
- 29 Apr · Compliance Certificate Under Regulation 40(9) & 40(10} Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Of Gennex Laboratories Limited For The Half Year Ended March 31, Z023;
  With reference to the above captioned subject matter, Pursuant to Regulation 40(9) & (10) of the SEBI (LODR) Regulations, 2015 enclosed please find the letter dated April 29, 2023, received .... (opens in a new tab)
- 20 Apr · Management
  In just concluded meeting of the board directors of the company, the board has considered and approve: 1. Appoint Mr. Dinesh Kumar Kejriwal as a Company Secretary & Compliance Officer .... (opens in a new tab)
- 20 Apr · Board meeting
  In just concluded meeting of the board directors of the company, the board has considered and approve: 1. Appoint Mr. Dinesh Kumar Kejriwal as a Company Secretary & Compliance Officer .... (opens in a new tab)
- 12 Apr · Board meeting
  Meeting on 20 Apr 2023
- 12 Apr · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/04/2023 ,inter alia, to consider and approve Pursuant to Regulation .... (opens in a new tab)
Mar 2023
- 20 Mar · Approval From The Factories Department Of Andhra Pradesh For The Change In The Name Of Factory And Occupier In Favour Of Deccan Remedies Limited
  Go through the enclosed Announcement (opens in a new tab)
- 2 Mar · Deccan Remedies Limited Acquired Pharma Unit Located JN Pharma City, Visakhapatnam
  Pursuant to concord entered between DRL and M/s. Forel Labs Private Limited (FLPL), DRL acquired live running US FDA (Food and Drug Administration) complied plant of FLPL located at Plot .... (opens in a new tab)
- 2 Mar · Business
  Pursuant to announcement of Board Meeting dated January 04, 2022, we hereby inform you 836,165 equity shares equivalent to 6.73% of Deccan Remedies Limited (DRL) acquired from the existing .... (opens in a new tab)
Feb 2023
Jan 2023
- 10 Jan · 01St (First) Reminder For First And Final Call Money Notice
  This has reference to our letter dated January 05, 2023, wherein we had informed that the Right Issue Committee ("Committee"), duly authorized by the Board of Directors of the Company approved .... (opens in a new tab)
- 5 Jan · 01St (First) Reminder For First And Final Call Money Of Gennex Laboratories Limited
  This has reference to our intimation dated November 04, 2022, wherein we had informed the exchange that the Company had received the successful and valid call money on 3,47,40,043 Partly .... (opens in a new tab)
Nov 2022
- 25 Nov · Disclosure Pursuant To Regulation 23(9) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended September 30, 2022
  Pursuant to the provision of Regulation.23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the attached note on Related party Transaction .... (opens in a new tab)
- 24 Nov · Disclosure
  Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 24, 2022 for VAB Ventures Ltd (opens in a new tab)
- 23 Nov · Disclosure
  Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for JMS Mining Pvt Ltd (opens in a new tab)
- 22 Nov · Disclosure
  Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on November .... (opens in a new tab)
- 22 Nov · Disclosure
  Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 22, 2022 for VAB Ventures Ltd (opens in a new tab)
- 21 Nov · Disclosure
  Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on November .... (opens in a new tab)
- 21 Nov · Disclosure
  Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 21, 2022 for VAB Ventures Ltd (opens in a new tab)
- 14 Nov · Results
  In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the .... (opens in a new tab)
- 14 Nov · Board meeting
  In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the .... (opens in a new tab)
- 4 Nov · Board meeting
  Meeting on 14 Nov 2022: quarterly results
- 4 Nov · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 ,inter alia, to consider and approve With reference to the .... (opens in a new tab)
- 4 Nov · Corporate action
  Outcome of the Rights Issue Committee Meeting: 1. Transition of Partly Paid-up Equity Shares in to fully paid-up equity shares; 2. Reminder to holders of remaining Partly Paid-up Shares. (opens in a new tab)
Oct 2022
- 28 Oct · Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended September 30, 2022
  With reference to the above captioned subject matter, we are hereby enclosing the Compliance certificate Pursuant to Regulation 7(2) & 7(3) of the SEBI (LODR) Regulations 2015 for the half .... (opens in a new tab)
- 15 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
  No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 0
- 15 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
  No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 0
- 12 Oct · First And Final Call Money Notice
  First and Final Call Money Notice in respect of 5,25,06,534 outstanding partly paid-up equity shares of face value ?1 each, issued by the Company, on a rights basis, pursuant to the Letter .... (opens in a new tab)
- 1 Oct · Meeting
  In compliance to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (Listing Regulations) please find enclosed herewith .... (opens in a new tab)
Sep 2022
- 30 Sep · Meeting
  Pursuant to Reg.30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of 37th Annual General Meeting (AGM) of the Company held on Friday, September 30, .... (opens in a new tab)
- 28 Sep · Revision Of Call Money Payment Period Of First And Final Call
  Pursuant to the outcome of the board meeting announced on September 26, 2022, Rights Issue Committee of the Company hereby inform you that as per the SEBI Circular, the Committee decide .... (opens in a new tab)

Gennex Laboratories share news and announcements

Jun 2023

May 2023

Apr 2023

Mar 2023

Feb 2023

Jan 2023

Nov 2022

Oct 2022

Sep 2022